TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Amorepacific has made a strategic investment in biotechnology company Junevity and partnered with it to research cosmetic approaches to skin ageing. The work will use Junevity’s RESET Platform to identify and validate gene-network pathways; no resulting product, development timeline or investment amount has been disclosed in the source report.
Amorepacific has invested in biotechnology company Junevity and partnered with it to research cosmetic applications of Junevity’s technology for skin ageing. The collaboration will combine Junevity’s RESET Platform with Amorepacific’s skin biology and product-development expertise, with Amorepacific set to lead development and commercialisation of any cosmetic products arising from the research.
The companies plan to use the RESET Platform to identify and validate biological pathways that could help shift gene networks associated with ageing skin toward what the partners describe as a healthier state. According to the report, the platform draws on human disease omics, genetic linkages, machine learning and artificial intelligence to identify transcription-factor targets. Transcription factors are proteins involved in regulating how genes are expressed.
The arrangement includes more than the strategic investment. Amorepacific and Junevity will collaborate on research, and they have also entered into a separate licensing agreement for cosmetic applications of the technology. Amorepacific will lead the development and commercialisation of products stemming from the research, while Junevity will continue developing therapeutic applications of its platform, the report said.
The source does not identify a specific product, indicate that a candidate has reached testing, or report results from the joint work. The announcement concerns a research and development collaboration, not a product launch or evidence that the approach can reverse skin ageing. The companies’ stated aim is to discover and validate relevant pathways before any resulting cosmetic application can be developed.
A New Route Into Skin-Aging Research
The deal brings computational biology and gene-network research into Amorepacific’s cosmetics research pipeline. If the partners identify pathways that can be translated into safe, useful cosmetic ingredients or products, the work could broaden the company’s approaches to skin ageing beyond established formulation research. That is a potential outcome, not a demonstrated result: the supplied report provides no findings, efficacy data or product timetable.
The partnership also separates the intended commercial paths. Amorepacific holds the lead for cosmetic development and commercialisation under the reported arrangement, while Junevity continues its therapeutic work. This may allow the two companies to apply research from a shared technology platform to different product areas, although the source does not detail the licensing terms or how the partners will divide rights beyond the stated cosmetic scope.
For consumers and the cosmetics industry, the immediate development is therefore strategic rather than retail-facing. It signals investment in a new research area, but it does not establish that a new treatment or cosmetic is available, nor that the platform has been shown to produce a measurable skin benefit.
anti-aging skin serum with gene network technology
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Research Partnership Is Structured
Amorepacific is a cosmetics company with expertise in skin biology, cosmetic development and commercialisation, according to the source report. Junevity is described as a biotechnology company whose RESET Platform uses biological and computational methods to identify targets connected to ageing. The collaboration brings those areas of expertise together for research focused on skin gene networks.
The reported work has two distinct tracks. The partners will investigate potential cosmetic applications through their research collaboration and licensing agreement. Junevity, meanwhile, will continue developing therapeutic applications of the underlying technology. The report does not specify whether the therapeutic work is part of this investment, or provide further detail about the investment structure.
The source report, published by Global Cosmetics News and citing a Business Wire release, frames the deal as part of Amorepacific’s investment in longevity-focused skin science. It supplies no amount for the investment, named research targets, development milestones or prior results from the RESET Platform in cosmetic use.
“The collaboration will combine Junevity’s RESET Platform with Amorepacific’s expertise in skin biology, cosmetic development and commercialisation.”
— Global Cosmetics News, summarising the companies’ announcement
skin rejuvenation creams with biotechnology
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Investment Terms and Results Not Disclosed
The supplied material does not disclose the investment amount, deal terms or research timeline. It also does not name specific transcription-factor targets or explain how the partners will define and measure a shift toward a healthier skin gene network.
No study results, product candidates, safety findings or consumer testing are reported. It remains unclear when the research could produce a cosmetic product, whether any candidate will advance to development, and what evidence would be used to support product claims. The stated aim of addressing skin ageing should not be read as proof that the technology can reverse ageing or deliver a particular benefit.
cosmetic products targeting skin aging pathways
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Research Must Produce Testable Candidates
The next reported step is joint research using the RESET Platform and Amorepacific’s skin-science capabilities to identify and validate relevant pathways. If the work yields candidates suitable for cosmetic development, Amorepacific is expected to lead their development and commercialisation under the reported licensing arrangement.
The source gives no dates for research milestones or product announcements. Further updates would be needed to establish which targets are selected, whether they are validated, and whether the partners move from discovery into product development. Junevity is also expected to continue its separate therapeutic applications work, but no specific milestone for that track was provided.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did Amorepacific announce?
Amorepacific invested in Junevity and agreed to work with the biotechnology company on research into cosmetic applications of its skin-aging technology.
What is Junevity’s RESET Platform?
According to the source report, it uses human disease omics, genetic linkages, machine learning and AI to identify transcription-factor targets. The partners plan to use it to investigate pathways associated with ageing skin.
Is a new skin-rejuvenation product available?
No. The announcement describes a research and development partnership. The supplied material does not name a product or provide a launch date.
Who will develop any cosmetic products?
The report says Amorepacific will lead development and commercialisation of products resulting from the research. Junevity will continue to develop therapeutic applications of its technology.
What is still unknown about the deal?
The investment amount, research timeline, specific targets, results and potential product milestones have not been disclosed in the supplied source material.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
